<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973826</url>
  </required_header>
  <id_info>
    <org_study_id>C3601007</org_study_id>
    <nct_id>NCT04973826</nct_id>
  </id_info>
  <brief_title>Study to Assess the Pharmacokinetics, Safety and Tolerability of Aztreonam-Avibactam in Healthy Chinese Participants.</brief_title>
  <official_title>A PHASE I, SINGLE CENTER, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM ADMINISTERED AS SINGLE AND REPEATED INTRAVENOUS DOSES IN HEALTHY CHINESE PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, single center, single arm, open-label study to assess the PK, safety and&#xD;
      tolerability of Aztreonam-Avibactam after single and repeated IV infusion of doses in healthy&#xD;
      Chinese participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2021</start_date>
  <completion_date type="Actual">September 27, 2021</completion_date>
  <primary_completion_date type="Actual">September 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 and Day 4</time_frame>
    <description>Maximum Observed Plasma Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC6</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time profile from time 0 to 6 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Day 1 and Day 4</time_frame>
    <description>Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration (Clast)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC24</measure>
    <time_frame>Day 1 and Day 4</time_frame>
    <description>Area under the plasma concentration-time profile from time 0 to 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Day 1 and Day 4</time_frame>
    <description>Area under the plasma concentration-time profile from time zero extrapolated to infinite time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau</measure>
    <time_frame>Day 4</time_frame>
    <description>Area under the plasma concentration-time profile from time 0 to to the time of the end of the dosing interval (τ), where τ=6 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC24,ss</measure>
    <time_frame>Day 4</time_frame>
    <description>Total daily area under the plasma concentration-time profile from time 0 to 24 hours at steady-state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Day 1 and Day 4</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss</measure>
    <time_frame>Day 4</time_frame>
    <description>Apparent volume of distribution at steady-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz</measure>
    <time_frame>Day 4</time_frame>
    <description>Apparent Volume of distribution during terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>Day 1 and Day 4</time_frame>
    <description>Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1 and Day 4</time_frame>
    <description>Time of observed maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac,cmax</measure>
    <time_frame>Day 4</time_frame>
    <description>Accumulation ratio for Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rac</measure>
    <time_frame>Day 4</time_frame>
    <description>Accumulation ratio for AUCτ following multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting an adverse event</measure>
    <time_frame>up to Day 35</time_frame>
    <description>To investigate the safety and tolerability of ATM-AVI as single and repeated intravenous (IV) infusions in healthy Chinese participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting abnormal vital signs</measure>
    <time_frame>Up to Day 35</time_frame>
    <description>To investigate the safety and tolerability of ATM-AVI as single and repeated intravenous (IV) infusions in healthy Chinese participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting abnormal ECGs</measure>
    <time_frame>Up to Day 35</time_frame>
    <description>To investigate the safety and tolerability of ATM-AVI as single and repeated intravenous (IV) infusions in healthy Chinese participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting abnormal laboratory assessments</measure>
    <time_frame>Up to Day 35</time_frame>
    <description>To investigate the safety and tolerability of ATM-AVI as single and repeated intravenous (IV) infusions in healthy Chinese participants.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ATM-AVI treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chinese healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aztreonam-Avibactam</intervention_name>
    <description>500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours</description>
    <arm_group_label>ATM-AVI treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Chinese male and female participants&#xD;
&#xD;
          -  No clinical relevant abnormalities&#xD;
&#xD;
          -  willing and able to comply with all study procedures&#xD;
&#xD;
          -  BMI:17.5-30.5&#xD;
&#xD;
          -  Sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinical significant illness&#xD;
&#xD;
          -  History of alcohol abuse&#xD;
&#xD;
          -  Use within 14 days prior the first study dose&#xD;
&#xD;
          -  CL&gt;80ml/min&#xD;
&#xD;
          -  Abnormal vital signs, such 12-ECG, blood pressure and pulse rate&#xD;
&#xD;
          -  Blood donation within 60days&#xD;
&#xD;
          -  History of HIV, HBsAg, HBcAb, HCVAb&#xD;
&#xD;
          -  Other medical or psychiatric may inappropriate for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huashan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201107</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3601007</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>no clinically relevant abnormalities</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aztreonam</mesh_term>
    <mesh_term>Avibactam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

